Back
52· Steady
Health & Science3h 58m ago
Germany's medicines regulator green-lit a psilocybin compassionate use program, the first in the European Union.
Archive Window: 7 Days Left
Germany (Berlin, Mannheim), European Union, Haarlem (Netherlands)
Who
Lea Mertens, Andrea Jungaberle, Josh Hardman
What
Germany's medicines regulator green-lit a psilocybin compassionate use program, the first in the European Union.
When
Tue, 16 Jun 2026 10:11:55 GMT · 3h 58m ago
Where
Germany (Berlin, Mannheim), European Union, Haarlem (Netherlands) ·
Why
The program is based on the EPIsoDE study, which formed the basis for compassionate use.
The Frontline Impact
How this affects you
This program provides a new pathway for patients with serious conditions to access psilocybin treatment, with ongoing efforts to secure public and private insurance coverage, potentially increasing accessibility beyond private health insurance holders.
Story chain
4 events in this thread- Health & Science3h 58m agoGermany's psilocybin compassionate use program is underway with early patient experiences and progress in securing insurance coverage.Open article
- Currently Reading3h 58m agoGermany's medicines regulator green-lit a psilocybin compassionate use program, the first in the European Union.
- Health & Science3h 58m agoGermany has green-lit the EU’s first psilocybin compassionate use program, with two centers, OVID Clinic Berlin and CIMH Mannheim, permitted to offer dosing.Open article
- Health & Science3h 58m agoGermany’s medicines regulator green-lit a psilocybin compassionate use program, the first such pathway in the European Union.Open article